144 related articles for article (PubMed ID: 34208655)
1. Spotlight on Accessory Proteins: RTK-RAS-MAPK Modulators as New Therapeutic Targets.
Pudewell S; Ahmadian MR
Biomolecules; 2021 Jun; 11(6):. PubMed ID: 34208655
[TBL] [Abstract][Full Text] [Related]
2. Accessory proteins of the RAS-MAPK pathway: moving from the side line to the front line.
Pudewell S; Wittich C; Kazemein Jasemi NS; Bazgir F; Ahmadian MR
Commun Biol; 2021 Jun; 4(1):696. PubMed ID: 34103645
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive pancancer genomic analysis reveals (RTK)-RAS-RAF-MEK as a key dysregulated pathway in cancer: Its clinical implications.
Imperial R; Toor OM; Hussain A; Subramanian J; Masood A
Semin Cancer Biol; 2019 Feb; 54():14-28. PubMed ID: 29175106
[TBL] [Abstract][Full Text] [Related]
4. Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers.
Sulahian R; Kwon JJ; Walsh KH; Pailler E; Bosse TL; Thaker M; Almanza D; Dempster JM; Pan J; Piccioni F; Dumont N; Gonzalez A; Rennhack J; Nabet B; Bachman JA; Goodale A; Lee Y; Bagul M; Liao R; Navarro A; Yuan TL; Ng RWS; Raghavan S; Gray NS; Tsherniak A; Vazquez F; Root DE; Firestone AJ; Settleman J; Hahn WC; Aguirre AJ
Cell Rep; 2019 Oct; 29(1):118-134.e8. PubMed ID: 31577942
[TBL] [Abstract][Full Text] [Related]
5. Breaking Oncogene Addiction: Getting RTK/RAS-Mutated Cancers off the SOS.
Sheffels E; Kortum RL
J Med Chem; 2021 May; 64(10):6566-6568. PubMed ID: 33961431
[TBL] [Abstract][Full Text] [Related]
6. RTK/Ras/MAPK signaling.
Sundaram MV
WormBook; 2006 Feb; ():1-19. PubMed ID: 18050474
[TBL] [Abstract][Full Text] [Related]
7. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
Wang AX; Qi XY
IUBMB Life; 2013 Sep; 65(9):748-58. PubMed ID: 23893853
[TBL] [Abstract][Full Text] [Related]
8. Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors.
Ming Z; Lim SY; Kefford RF; Rizos H
Pigment Cell Melanoma Res; 2020 Mar; 33(2):345-357. PubMed ID: 31518489
[TBL] [Abstract][Full Text] [Related]
9. Mammalian Sprouty4 suppresses Ras-independent ERK activation by binding to Raf1.
Sasaki A; Taketomi T; Kato R; Saeki K; Nonami A; Sasaki M; Kuriyama M; Saito N; Shibuya M; Yoshimura A
Nat Cell Biol; 2003 May; 5(5):427-32. PubMed ID: 12717443
[TBL] [Abstract][Full Text] [Related]
10. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.
Friday BB; Adjei AA
Clin Cancer Res; 2008 Jan; 14(2):342-6. PubMed ID: 18223206
[TBL] [Abstract][Full Text] [Related]
11. Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade.
Avruch J; Khokhlatchev A; Kyriakis JM; Luo Z; Tzivion G; Vavvas D; Zhang XF
Recent Prog Horm Res; 2001; 56():127-55. PubMed ID: 11237210
[TBL] [Abstract][Full Text] [Related]
12. Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling.
Rukhlenko OS; Khorsand F; Krstic A; Rozanc J; Alexopoulos LG; Rauch N; Erickson KE; Hlavacek WS; Posner RG; Gómez-Coca S; Rosta E; Fitzgibbon C; Matallanas D; Rauch J; Kolch W; Kholodenko BN
Cell Syst; 2018 Aug; 7(2):161-179.e14. PubMed ID: 30007540
[TBL] [Abstract][Full Text] [Related]
13. MEK and RAF inhibitors for BRAF-mutated cancers.
Belden S; Flaherty KT
Expert Rev Mol Med; 2012 Oct; 14():e17. PubMed ID: 23058743
[TBL] [Abstract][Full Text] [Related]
14. EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.
Phuchareon J; McCormick F; Eisele DW; Tetsu O
Proc Natl Acad Sci U S A; 2015 Jul; 112(29):E3855-63. PubMed ID: 26150526
[TBL] [Abstract][Full Text] [Related]
15. The protein kinase MAP3K19 phosphorylates MAP2Ks and thereby activates ERK and JNK kinases and increases viability of KRAS-mutant lung cancer cells.
Hoang VT; Nyswaner K; Torres-Ayuso P; Brognard J
J Biol Chem; 2020 Jun; 295(25):8470-8479. PubMed ID: 32358059
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel induces prolonged activation of the Ras/MEK/ERK pathway independently of activating the programmed cell death machinery.
Okano J ; Rustgi AK
J Biol Chem; 2001 Jun; 276(22):19555-64. PubMed ID: 11278851
[TBL] [Abstract][Full Text] [Related]
17. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
18. Phosphatidylinositol 3-kinase requirement in activation of the ras/C-raf-1/MEK/ERK and p70(s6k) signaling cascade by the insulinomimetic agent vanadyl sulfate.
Pandey SK; Théberge JF; Bernier M; Srivastava AK
Biochemistry; 1999 Nov; 38(44):14667-75. PubMed ID: 10545192
[TBL] [Abstract][Full Text] [Related]
19. Resistance to MEK inhibitors: should we co-target upstream?
Poulikakos PI; Solit DB
Sci Signal; 2011 Mar; 4(166):pe16. PubMed ID: 21447797
[TBL] [Abstract][Full Text] [Related]
20. Mitogenic effect of oxidized low-density lipoprotein on vascular smooth muscle cells mediated by activation of Ras/Raf/MEK/MAPK pathway.
Yang CM; Chien CS; Hsiao LD; Pan SL; Wang CC; Chiu CT; Lin CC
Br J Pharmacol; 2001 Apr; 132(7):1531-41. PubMed ID: 11264247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
